The new guideline advocates use of plasmapheresis for treatment of severe relapses in multiple sclerosis, severe AIDP/Guillain-Barre syndrome, and short-term management of CIDP.

AIDP can become chronic inflammatory demyelinating polyneuropathy (CIDP), a neurological disorder that causes progressive weakness and loss of sensation in the arms and legs.

“With today’s publication in The Lancet Neurology, we are also advancing scientific knowledge of the disease biology underlying CIDP and thereby helping to progress further innovation with the ...

Sanofi's antibody riliprubart has received orphan drug designation (ODD) from Japan's Ministry of Health, Labour and Welfare (MHLW) for its potential to treat chronic inflammatory demyelinating ...

A phase 3 trial of patients with a rare neurological condition, CIDP, data demonstrate that long-term treatment with Gamunex improves and maintains health-related quality of life, a significant ...

“With today’s publication in The Lancet Neurology, we are also advancing scientific knowledge of the disease biology underlying CIDP and thereby helping to progress further innovation with the ...

With over 600 recognized rare neurological disorders, many patients face misdiagnosis or lengthy diagnostic journeys before proper care is provided. Only 10% of these conditions have FDA-approved ...

Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv ...